Business Context and Reporting Period
Company: DaVita Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2002
Business Overview: DaVita operates dialysis centers and laboratories, primarily in the continental United States. The company completed the divestiture of its remaining non-continental U.S. operations (Puerto Rico) on June 1, 2002.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2002 | Six Months Ended June 30, 2001 |
|---|---|---|
| Net Operating Revenues | $870.3 million | $786.9 million |
| Operating Income | $159.8 million | $145.9 million |
| Net Income | $44.3 million | $60.5 million |
| Diluted EPS (Net Income) | $0.54 | $0.68 |
| Operating Cash Flow | $146.1 million | $134.8 million |
| Cash and Equivalents (End of Period) | $137.0 million | $85.3 million |
| Total Long-Term Debt | $1,316.2 million | $811.2 million |
Note: Net income for the six months ended June 30, 2002, includes an extraordinary loss of $29.4 million related to the early extinguishment of debt.
Material Changes vs. Prior Period
- Recapitalization and Debt Restructuring: In March and April 2002, DaVita initiated a recapitalization plan. The company repurchased all $225 million of its 9.875% Senior Subordinated Notes due 2011 for approximately $266 million, resulting in a $29.4 million extraordinary loss. Concurrently, the company secured a new $1.115 billion senior credit facility.
- Stock Repurchases: The company repurchased 19.8 million shares of common stock for approximately $474 million during the first six months of 2002, including a tender offer of 16.7 million shares at $24 per share in June 2002.
- Revenue Growth: Continental U.S. revenues increased 11% year-over-year to $441 million for the quarter, driven by a 5.5% increase in average revenue per treatment and a 4.5% same-center growth rate.
- Divestiture: Completed the sale of remaining non-continental U.S. operations in Puerto Rico, recognizing a recovery gain of $1.4 million on previously impaired assets.
- Accounting Changes: Adopted SFAS No. 142, eliminating goodwill amortization effective January 1, 2002.
Guidance, Outlook, and Risks
Management Commentary and Guidance
- EBITDA Projections: Management projects 2002 EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) to be in the range of $360 million to $380 million. 2003 projections are expected to be in the same range.
- Growth Outlook: Same-center growth is expected to remain in the 3.0% to 5.0% range for the remainder of 2002 and into 2003.
- Liquidity: The company believes it has sufficient liquidity and operating cash flows to fund capital investments, debt service, and planned stock repurchases over the next 12 months.
Risks and Contingencies
- Regulatory Reviews: The company is subject to ongoing reviews by the Department of Justice (DOJ), the Office of Inspector General (OIG), and Medicare carriers regarding billing practices and financial relationships with physicians. A Florida-based laboratory subsidiary faces a carrier review with potential overpayment determinations totaling approximately $19.8 million for the first two review periods (though a judge recently ruled the sampling procedures invalid for these periods).
- Reimbursement Rates: Approximately 51% of revenues come from Medicare. There is a risk of future declines or lack of increases in reimbursement rates, which have not kept pace with inflation. Additionally, changes in clinical practices regarding EPO (Erythropoietin) administration could reduce revenue.
- Medical Director Agreements: The company relies on physicians for patient referrals. Failure to renew medical director agreements could negatively impact same-center growth.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the new $1.115 billion senior credit facility covenants, particularly leverage ratios, given the increased debt load from the recapitalization.
- Regulatory Resolution: Monitor the status of the DOJ and OIG investigations and the final outcome of the Medicare carrier review for the Florida laboratory, as adverse resolutions could result in substantial penalties.
- Stock Repurchase Authorization: Track the utilization of the remaining $225 million stock repurchase authorization approved in May 2002.
- EBITDA Realization: Compare actual quarterly EBITDA against the projected $360-$380 million range for 2002 to assess operational performance excluding the impact of the extraordinary debt loss.
- Medical Director Retention: Review the renewal rate of medical director agreements, specifically the 36 centers requiring renewal by June 30, 2003.